Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study

Abdullah M. Alrajhi, Bashayer Alshehri, Walaa A. Alshahrani, Arwa AlHaj Issa, Amal H. Alotaibi, Areej Abumustafa, Ghadah Alyousif, Nora Alkhudair, Mai Alalawi, Nada Alsuhebany, Mohammed Alzahrani, Abrar Alghamdi, Ramesh Vishwakarma, Abrar Bakr, Zahra AlHaj Issa, Abdullah Alateeq, Abeer A. Alenazi, Mashael S. Alaboud, Badr Alayaf, Homood M. As Sobeai, Khalid Al Sulaiman

Open source

DOI: 10.1080/16078454.2026.2700811
Published: 2026-07-10
Container: Hematology
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/16078454.2026.2700811,
  title = {Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study},
  author = {Abdullah M. Alrajhi and Bashayer Alshehri and Walaa A. Alshahrani and Arwa AlHaj Issa and Amal H. Alotaibi and Areej Abumustafa and Ghadah Alyousif and Nora Alkhudair and Mai Alalawi and Nada Alsuhebany and Mohammed Alzahrani and Abrar Alghamdi and Ramesh Vishwakarma and Abrar Bakr and Zahra AlHaj Issa and Abdullah Alateeq and Abeer A. Alenazi and Mashael S. Alaboud and Badr Alayaf and Homood M. As Sobeai and Khalid Al Sulaiman},
  year = {2026},
  journal = {Hematology},
  doi = {10.1080/16078454.2026.2700811},
  url = {https://doi.org/10.1080/16078454.2026.2700811}
}

RIS

TY  - JOUR
TI  - Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study
AU  - Abdullah M. Alrajhi
AU  - Bashayer Alshehri
AU  - Walaa A. Alshahrani
AU  - Arwa AlHaj Issa
AU  - Amal H. Alotaibi
AU  - Areej Abumustafa
AU  - Ghadah Alyousif
AU  - Nora Alkhudair
AU  - Mai Alalawi
AU  - Nada Alsuhebany
AU  - Mohammed Alzahrani
AU  - Abrar Alghamdi
AU  - Ramesh Vishwakarma
AU  - Abrar Bakr
AU  - Zahra AlHaj Issa
AU  - Abdullah Alateeq
AU  - Abeer A. Alenazi
AU  - Mashael S. Alaboud
AU  - Badr Alayaf
AU  - Homood M. As Sobeai
AU  - Khalid Al Sulaiman
PY  - 2026
JO  - Hematology
DO  - 10.1080/16078454.2026.2700811
UR  - https://doi.org/10.1080/16078454.2026.2700811
ER  -

APA

Alrajhi, A. M., Alshehri, B., Alshahrani, W. A., Issa, A. A., Alotaibi, A. H., Abumustafa, A., Alyousif, G., Alkhudair, N., Alalawi, M., Alsuhebany, N., Alzahrani, M., Alghamdi, A., Vishwakarma, R., Bakr, A., Issa, Z. A., Alateeq, A., Alenazi, A. A., Alaboud, M. S., Alayaf, B., Sobeai, H. M. A., & Sulaiman, K. A. (2026). Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study. Hematology. https://doi.org/10.1080/16078454.2026.2700811

Source records

crossref · retrieved 2026-11-10T19:55:23.616Z